NEW YORK, May 21, 2018 /PRNewswire-PRWeb/ -- Koneksa Health, an early-stage company focused on the integration of real-world data into clinical research, announced today that it will present results of its validation study of remote FEV1 measurements at the American Thoracic Society (ATS) International Conference being held May 18-23 in San Diego, CA.
"Patients contributing pulmonary function measures twice daily demonstrated the potential to detect clinically meaningful changes in FEV1 with fewer than 20 subjects," said Marcie Ruddy, one of the study's authors, and Vice President of Clinical Development for Respiratory and Inflammation at Regeneron Pharmaceuticals. "The use of this model in investigational studies may provide signal detection very early in the drug development process."
The abstract, "Validating Remote FEV1 Monitoring in Moderate Asthmatics to Increase Study Power," will be presented at the American Thoracic Society International Conference in San Diego at a Thematic Poster Session on "Asthma: Pathophysiology and Clinical Trials" on Monday, May 21.
"The careful validation of new technology for clinical trials is creating digital biomarkers vastly increasing the data available per patient, with potential to even reduce the number of site visits," said Chris Benko, CEO of Koneksa Health. "The dramatic reduction in sample-size requirements that this study shows is encouraging and reflective of the efficiency that these tools can provide."
Poster details: 7841 - Validating Remote FEV1 Monitoring in Moderate Asthmatics to Increase Study Power B65 - Asthma: Pathophysiology and Clinical Trials Monday May 21, 2018 9:15 AM - 4:15 PM
The complete text of the abstract is available online at https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A3934
About Koneksa Health
Koneksa Health is a private technology company focused on transforming the way health is measured by incorporating real-world data into clinical research. Koneksa is committed to improving patient care and health outcomes, by opening effective new avenues of data collection through emergent technology. Koneksa works primarily to augment clinical trials with real-world data gathered through mobile, wearable and other digital technologies.
For more information, please visit http://www.koneksahealth.com.
SOURCE Koneksa Health
Advertisement
"Patients contributing pulmonary function measures twice daily demonstrated the potential to detect clinically meaningful changes in FEV1 with fewer than 20 subjects," said Marcie Ruddy, one of the study's authors, and Vice President of Clinical Development for Respiratory and Inflammation at Regeneron Pharmaceuticals. "The use of this model in investigational studies may provide signal detection very early in the drug development process."
Advertisement
The abstract, "Validating Remote FEV1 Monitoring in Moderate Asthmatics to Increase Study Power," will be presented at the American Thoracic Society International Conference in San Diego at a Thematic Poster Session on "Asthma: Pathophysiology and Clinical Trials" on Monday, May 21.
"The careful validation of new technology for clinical trials is creating digital biomarkers vastly increasing the data available per patient, with potential to even reduce the number of site visits," said Chris Benko, CEO of Koneksa Health. "The dramatic reduction in sample-size requirements that this study shows is encouraging and reflective of the efficiency that these tools can provide."
Poster details: 7841 - Validating Remote FEV1 Monitoring in Moderate Asthmatics to Increase Study Power B65 - Asthma: Pathophysiology and Clinical Trials Monday May 21, 2018 9:15 AM - 4:15 PM
The complete text of the abstract is available online at https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A3934
About Koneksa Health
Koneksa Health is a private technology company focused on transforming the way health is measured by incorporating real-world data into clinical research. Koneksa is committed to improving patient care and health outcomes, by opening effective new avenues of data collection through emergent technology. Koneksa works primarily to augment clinical trials with real-world data gathered through mobile, wearable and other digital technologies.
For more information, please visit http://www.koneksahealth.com.
SOURCE Koneksa Health
